This site is intended for health professionals only

Angioplasty trumps drugs

teaser

Angioplasty is more effective than medical therapy for preventingcardiac events in patients with silent ischaemia following myocardialinfarction (MI), results of a randomised controlled trial suggest.

Silentischaemia is associated with an adverse prognosis after MI but optimaltreatment is unknown. A recent study, however, has suggested that drugsplus percutaneous coronary intervention (PCI) may offer short-termbenefits.

To investigate, Dr Paul Erne of KantonsspitalLuzern, Switzerland, and colleagues undertook a randomised controlledstudy, the Swiss Interventional Study on Silent Ischaemia Type II(SWISSI II). The participants included 201 patients with a recent MIand silent myocardial ischaemia verified by stress imaging.

Studyparticipants were randomly assigned to either receive PCI aimed at fullrevascularisation or intensive anti-ischaemic drug therapy usingbisoprolol, amlodipine, molsidomine, or combinations thereof. Medicaltherapy was uptitrated with the aim of eliminating silent ischaemiaduring exercise testing, the researchers say.

In addition,all patients received aspirin and a statin, and hypertension wasmanaged with angiotensin-converting enzyme inhibitors.

After10.2 years’ follow-up there had been 27 major adverse cardiac events(cardiac death, nonfatal MI and/or symptom-driven revascularisation) inthe PCI group versus 67 in the drug-therapy group.

This gavean adjusted hazard ratio of 0.33 (p<0.001) or an absolute eventreduction of 6.3% per year (p<0.001) in favour of PCI, the authorsreport.

Other significant benefits of PCI versus medicaltherapy included lower rates of ischaemia and preservationAA ofleft-ventricular ejection fraction throughout the study period.

“Wefound a persistent benefit of PCI compared with optimised drug therapywhich became apparent only after two years of observation, withsurvival curves continuously diverging up to the final follow-up after10 years,” the authors say.

“Our findings argue for an ischaemic-targeted approach to PCI among asymptomatic survivors of MI.”

JAMA 2007;297:1985-91

 






Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine

x